... half of the world's population is infected with H. pylori and does not know it ...

It’s estimated that half the global population is infected with H. pylori. Approximately one in six of H. pylori infection develops peptic ulcer disease and a small portion of H. pylori infection leads to gastric cancer.

Several methods can be used to diagnose Helicobacter pylori infection.

Current guidelines for the management of H pylori infection recommend eradication treatment without performing endoscopy in patients (< 45 years of age) with no alarm symptoms, thus making the availability of simple and reliable noninvasive tests important. Currently available noninvasive tests for the diagnosis of H pylori infection include stool antigen test and detection of anti-H pylori antibodies (e.g. serology).

DIA.PRO ELISA assay for determination of Helicobacter pylori Antigen (code HPAG.CE.96) is a non-invasive test that detects antigens directly in human stool specimen. The test is qualitative/quantitative, very specific and may be used for various purposes:

•             follow-up of HP-infected patients

•             monitor the effectiveness of therapeutic treatment

•             confirm the eradication of H. pylori in patients


Diagnostic performances: 98% sensitivity, 96% specificity

Format: 96 tests

Shelf life: 18 months

Furthermore Diachel offers a complete solution for the serological antibodies detection to H. Pylori (IgG, IgA and IgM).